Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. tremipen

Tremipen

The first simple monitoring device for Parkinson and other Tremor diseases

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Tremipen project word cloud

Explore the words cloud of the Tremipen project. It provides you a very rough idea of what is the project "Tremipen" about.

equivalent    see    million    accumulated    stored    shown    life    company    accurate    simply    doctors    day    predict    hypertension    observation    act    health    electromyography    small    months    disease    expensive    solutions    direct    tremor    units    competitiveness    forecast    helpless    instead    sales    none    ups    psychological    tremors    display    tool    parkinson    tremipen    follow    quality    apps    phone    home    monitoring    mostly    exposed    worldwide    first    et    treatment    ing    check    patient    subjective    empowerment    suffer    software    amplitude    though    certified    24h    diseases    feel    device    subsequent    visits    depressions    26    patients    time    substitute    acute    clinical    nor    commercialization    affection    pen    boost    diabetes    100    many    register    seconds    medical    diagnosis    profit    accelerometers    pd   

Project "Tremipen" data sheet

The following table provides information about the project.

Coordinator		 TREMITAS GMBH 

Organization address
address: Lakeside B01
city: Klagenfurt
postcode: 9020
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Austria [AT]
 Project website http://www.tremitas.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.4. (Active ageing and self-management of health)
2. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.1.6. (Health care provision and integrated care)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-12-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TREMITAS GMBH AT (Klagenfurt) coordinator 50˙000.00

Map

 Project objective

Many health conditions like diabetes or hypertension have simple measurement devices. However, there is no equivalent for Parkinson´s Disease (PD) or Essential Tremor (ET), making an accurate clinical diagnosis and follow-up of these diseases a challenge. Instead, current check-ups and diagnosis of PD/ET are mostly carried out using subjective methods based simply on observation during visits (every 6 months). Even though there are some traditional solutions for Tremor monitoring, such as Electromyography or accelerometers, these are large devices which are expensive, take long time to use and provide no direct information for the patient, and though new solutions are being developed (such as 24h devices or phone apps), these are not 100% accurate, nor certified for their medical use. Moreover, none of the existing/developing solutions consider the psychological affection of patients, who feel helpless exposed to the disease and often suffer depressions. Our goal with Tremipen is to offer the first simple, small, easy-to-use, reliable and cost-effective device for PD and ET home-monitoring: a pen-like device, which just needs to be held for 60 seconds a day, to register the amplitude of the tremors. This information (which is shown in a display for the patients to see) is also stored for the subsequent analysis of doctors (with a tailored software), enabling a monitoring of the disease between visits. In this way, Tremipen does not aim to substitute doctors, but to act as a tool to help monitoring and treatment, while promoting patients´ empowerment and improving patients’ life quality for the over 10 million patients of PD/ET worldwide. Moreover, through this project we aim to boost the growth and competitiveness of our company: Early forecast predict sales of over 26,000 units 3 years after commercialization, resulting in €10.1 Million of accumulated profit.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TREMIPEN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TREMIPEN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.4.;H2020-EU.2.1.1.;H2020-EU.2.3.1.;H2020-EU.3.1.6.)

CLINICOVERY (2018)

CLINICOVERY, a versatile, high quality, environmental-friendly, easy to use e-Clinical solution for clinical research

Read More  

ImmuneHunter (2017)

Bioinformatics platform for profiling of health: allowing early and accurate detection of multiple diseases simultaneously

Read More  

SensUS (2018)

SensUS: A non-invasive and quantitative ultrasound (QUS) device for an objective monitoring of the childbirth labour process.

Read More